Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Icy Hot SmartRelief Latest TENS Target Is Back Pain

This article was originally published in The Tan Sheet

Executive Summary

Chattem rolls out Icy Hot SmartRelief Back & Hip device for drug-free pain relief for sore or aching muscles, chronic pain and arthritis, the Sanofi subsidiary says. The Back & Hip and Knee & Shoulder products feature the same control unit but different electrode pads, with refills sold without a control unit.

You may also be interested in...



OTC Self-Care Device Market Counts TENS As Growth Predictor

Sales of self-care devices for pain, allergies and cold sores are on the rise, with the pain treatment category growing double digits as consumers seek non-drug alternatives. Kline Group analyst Laura Mahecha discusses prospects of the devices, which are anticipated to take up more retail shelf space in coming years.

OTC Self-Care Device Market Counts TENS As Growth Predictor

Sales of self-care devices for pain, allergies and cold sores are on the rise, with the pain treatment category growing double digits as consumers seek non-drug alternatives. Kline Group analyst Laura Mahecha discusses prospects of the devices, which are anticipated to take up more retail shelf space in coming years.

First-In-Class Nasacort OTC Also Originates ‘Children’s’ Label

Sanofi introduces Children’s Nasacort Allergy 24HR in the same formulation and dosage as the original OTC switch, but with “children’s” added to the package after approval by FDA. The firm promotes the product as the “first and only” 24-hour multi-symptom nasal allergy spray available OTC for children ages 2 and up.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS108080

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel